Rajul Jain
Managing Director Vida Ventures
Rajul Jain is a Managing Director of Vida Ventures where he has served as an investor and as an investor-operator since 2019 to build world-class biotechnology companies and to develop novel therapies to treat areas of unmet medical need.
Dr. Jain is a Director of A2 Bio, Halda Therapeutics, Quanta Therapeutics, and Third Arc Bio. He was previously a Director of Capstan Therapeutics (acquired by AbbVie), InduPro, InnoSkel, LB Pharma (LBRX), and Neogene Therapeutics (acquired by Astra Zeneca), among others, and has participated in and led investments in several other Vida portfolio companies.
Prior to joining Vida, Dr. Jain was most recently Chief Medical Officer at Kite Pharma where he was involved with the global regulatory approvals of Yescarta and Tecartus. Previously, he was Global Development Leader at Amgen. He earned his B.A. in Chemistry and Biochemistry from Rice University, M.D. from Southwestern Medical school, post-doctoral fellowship in Biophysics at Rockefeller University, and oncology fellowship at MD Anderson Cancer Center. He was previously a volunteer Attending Physician treating underserved patients at UCLA Harbor Medical Center and continues to lecture regularly at UCLA.
Seminars
- What are the driving factors behind recent deals, what are the unique aspects of LNP technology that investors are most focused on?
- What key factors do investors evaluate when assessing the potential and risks of LNP technologies?
- Beyond individual drug candidates, how do investors envision the broader potential and future impact of these LNP partnerships?
